Health Care [ 9/12 ] | Biotechnology [ 63/75 ]
NASDAQ | Common Stock
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | -0.49 Decreased by -11.36% | -0.47 Decreased by -3.88% |
| Aug 12, 24 | -0.45 Increased by +10.00% | -0.41 Decreased by -9.76% |
| May 6, 24 | -0.37 Increased by +30.19% | -0.44 Increased by +15.91% |
| Mar 11, 24 | -0.49 Increased by +5.77% | -0.49 |
| Nov 6, 23 | -0.44 Increased by +30.16% | -0.46 Increased by +4.35% |
| Aug 10, 23 | -0.50 Increased by +1.96% | -0.57 Increased by +12.28% |
| May 8, 23 | -0.53 Increased by +10.17% | -0.54 Increased by +1.85% |
| Mar 16, 23 | -0.52 Increased by +10.34% | -0.54 Increased by +3.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -34.57 M Decreased by -35.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -31.96 M Decreased by -39.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -25.01 M Decreased by -13.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.54 M Increased by +N/A% | -28.33 M Decreased by -44.73% | Decreased by -1.84 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -25.48 M Decreased by -6.32% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -22.94 M Decreased by -15.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -21.96 M Increased by +4.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -19.57 M Increased by +14.04% | Decreased by N/A% Decreased by N/A% |